[Adjuvant measures after primary surgery of ovarian cancer].
Universitäts-Frauenklinik, Freiburg.
T
T
Bauknecht
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D015996:Survival Rate
D000911:Antibodies, Monoclonal; D007155:Immunologic Factors; D009944:Organoplatinum Compounds
Adjuvante Massnahmen nach primär operiertem Ovarialkarzinom.